Federated Hermes Inc. Acquires 11,018 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Federated Hermes Inc. increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 71.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,483 shares of the company’s stock after buying an additional 11,018 shares during the period. Federated Hermes Inc. owned about 0.07% of Tarsus Pharmaceuticals worth $720,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. RTW Investments LP raised its holdings in shares of Tarsus Pharmaceuticals by 9.4% in the fourth quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock valued at $63,835,000 after acquiring an additional 271,640 shares in the last quarter. Cowen AND Company LLC raised its holdings in shares of Tarsus Pharmaceuticals by 3.5% in the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after acquiring an additional 74,855 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after acquiring an additional 231,131 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Tarsus Pharmaceuticals in the first quarter valued at about $48,380,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $28,904,000. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reiterated an “outperform” rating and issued a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $51.60.

Tarsus Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:TARS opened at $34.51 on Monday. The business’s 50-day moving average is $27.44 and its 200 day moving average is $31.02. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. Tarsus Pharmaceuticals, Inc. has a 1 year low of $12.57 and a 1 year high of $42.50. The firm has a market capitalization of $1.30 billion, a P/E ratio of -7.23 and a beta of 1.06.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The business had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. During the same quarter in the previous year, the firm earned ($1.17) earnings per share. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.